文献速递创伤与烧伤心脑血管急症重症综合管理与镇静镇痛

平衡安全与疗效:创伤性脑损伤患者基于体重、抗Xa因子引导的依诺肝素静脉血栓栓塞预防给药策略评估

Balancing safety and efficacy: Assessment of a weight-based, anti-Xa-guided enoxaparin venous thromboembolism prophylaxis dosing strategy for traumatic brain injury patients.
PubMed 文献 · J Trauma Acute Care Surg · 2025-06-10
一句话结论在合并颅内出血的创伤性脑损伤患者中,基于体重、抗Xa因子引导的依诺肝素给药与静脉血栓栓塞发生率降低相关,且未增加颅内出血进展。

本研究为单中心、学术型、一级创伤中心的回顾性前后对照准实验研究,纳入2017年12月至2023年5月收治的成人创伤性脑损伤且CT证实颅内出血、接受至少24小时药物预防的患者。比较基于体重、抗Xa因子引导的依诺肝素方案与固定剂量依诺肝素(40 mg)每日一次或普通肝素(5,000单位)每日两至三次。经1:1倾向性评分匹配后252对队列比较,抗Xa因子引导组静脉血栓栓塞发生率显著更低(2.4% vs. 6.4%;p=0.029),影像学颅内出血进展两组相当(4.4% vs. 4.4%;p=0.99)。亚组匹配分析(各208例)同样显示抗Xa因子引导组静脉血栓栓塞发生率显著更低(1.4% vs. 5.8%;p=0.032),颅内出血进展无差异(4.3% vs. 2.4%;p=0.28)。

要点

  • 合并颅内出血的成人创伤性脑损伤患者,基于体重、抗Xa因子引导的依诺肝素预防较固定剂量方案静脉血栓栓塞发生率更低(2.4% vs. 6.4%;p=0.029)。
  • 抗Xa因子引导组与固定剂量组影像学颅内出血进展相当(4.4% vs. 4.4%;p=0.99),未观察到出血进展增加。
  • 亚组匹配分析中抗Xa因子引导组静脉血栓栓塞发生率亦更低(1.4% vs. 5.8%;p=0.032),颅内出血进展无差异(4.3% vs. 2.4%;p=0.28)。
  • 研究为单中心回顾性前后对照准实验设计,证据等级为治疗/管理Level IV。

适用人群与场景

  • 成人创伤性脑损伤患者,CT影像识别颅内出血,2017年12月至2023年5月入住单中心学术型一级创伤中心,接受至少24小时药物预防。

处置流程与药物剂量

  • 抗Xa因子引导组采用基于体重、抗Xa因子引导的依诺肝素给药方案。
  • 对照组采用固定剂量依诺肝素40 mg每日一次,或普通肝素5,000单位每日两至三次。

研究设计与关键结果

  • 回顾性前后对照准实验研究,单中心学术型一级创伤中心,纳入831例,经1:1倾向性评分匹配后比较252对队列。
  • 抗Xa因子引导组静脉血栓栓塞发生率2.4% vs. 固定剂量组6.4%(p=0.029),抗Xa因子引导组更低。
  • 影像学颅内出血进展抗Xa因子引导组4.4% vs. 固定剂量组4.4%(p=0.99),两组相当。
  • 亚组倾向性评分匹配分析各208例,抗Xa因子引导组静脉血栓栓塞发生率1.4% vs. 仅依诺肝素对照组5.8%(p=0.032),抗Xa因子引导组更低。
  • 亚组分析影像学颅内出血进展抗Xa因子引导组4.3% vs. 仅依诺肝素对照组2.4%(p=0.28),无差异。

证据类型、等级与局限

  • 证据类型:回顾性前后对照准实验研究;证据等级:治疗/管理Level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在合并颅内出血的创伤性脑损伤患者中,基于体重、抗Xa因子引导的依诺肝素给药与静脉血栓栓塞发生率降低相关,且未增加颅内出血进展。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with traumatic brain injury (TBI) with intracranial hemorrhage (ICH) are at high risk for venous thromboembolism (VTE) but are also prone to hemorrhagic progression. The efficacy and safety of weight-based, anti-Xa-guided enoxaparin dosing for patients with ICH are unknown. Therefore, this study aimed to compare fixed chemoprophylaxis versus weight-based, anti-Xa-guided enoxaparin dosing in the setting of ICH, hypothesizing reduced VTE incidence with similar ICH progression with weight-based, anti-Xa-guided dosing.

METHODS: This was a retrospective pre-post, quasi-experimental study conducted at a single, academic, Level I trauma center. Adult TBI patients admitted from December 2017 to May 2023 with ICH identified on computed tomography imaging who received at least 24 hours of chemoprophylaxis were included. A weight-based, anti-Xa-guided enoxaparin arm was compared with fixed doses of enoxaparin (40 mg) daily or unfractionated heparin (5,000 units) two to three times daily. Treatment groups were compared using a 1:1 propensity score matching (PSM), which matched for demographics and injury profile.

RESULTS: Of 831 included patients, 252 PSM cohorts were compared. A significantly lower incidence of VTE was observed in the anti-Xa-guided cohort (2.4% vs. 6.4%; p = 0.029), while radiographic ICH progression was equivalent between the two cohorts (4.4% vs. 4.4%; p = 0.99). A subgroup PSM analysis comparing 208 patients each from the anti-Xa-guided versus enoxaparin-only control cohort also demonstrated a significantly lower incidence of VTE with the anti-Xa-guided treatment (1.4% vs. 5.8%; p = 0.032) with no difference in radiographic ICH progression (4.3% vs. 2.4%; p = 0.28).

CONCLUSION: Weight-based, anti-Xa-guided enoxaparin dosing was associated with reduced VTE incidence without increased ICH progression in TBI patients with existing ICH.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Atallah S, Lee BJ, Lo A, et al. Balancing safety and efficacy: Assessment of a weight-based, anti-Xa-guided enoxaparin venous thromboembolism prophylaxis dosing strategy for traumatic brain injury patients. J Trauma Acute Care Surg. 2025. PMID: 40492862. doi:10.1097/TA.0000000000004701

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。